Profound Research’s Post

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Join me on April 23 to hear perspectives from top clinical research experts and disease area specialists on Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠 Learn about development challenges in each, how they were overcome, and the shared lessons that can propel novel approaches to more effective clinical trials.   Register now to secure your spot and join in this innovative conversation! #Alzheimers #MultipleSclerosis #ClinicalTrials #Biotech

Yesterday, our New York office wore purple in support of Alzheimer's Awareness Month. At GQR, we stand united in our commitment to raise awareness and contribute to the fight against Alzheimer's and other brain disorders. June marks a crucial period to spotlight the millions affected by these conditions. Our dedication to advancing the pharmaceutical field is at the heart of our mission to drive meaningful change and improve lives. 🔬 Innovation and Expertise: As a leading partner in the pharmaceutical industry, GQR Life Sciences is at the forefront of groundbreaking research and development. We tirelessly support the discovery of new treatments and therapies that hold the promise of a brighter future for those living with Alzheimer's and other neurological conditions. 💜 Community and Care: Real progress comes from collaborative effort. By working closely with our clients, researchers, and healthcare professionals, we foster an environment where innovation thrives and compassionate care is prioritized. 🌍 Global Impact: With our global reach, we connect top talent with cutting-edge projects worldwide. We are proud to contribute to a collective mission that spans continents, bringing us closer to breakthroughs that can transform lives. Join us this month in spreading awareness and supporting those affected by Alzheimer's. Together, we can drive the change needed to combat this devastating disease. #GQRlifesciences #GQRcares #LifeatGQR #alzheimersawareness #GQR

Exciting News: In a recent study published in JAMA, a medication called Donanimab has shown significant potential in reducing the progression of Alzheimer's disease. Watch the full video on youtube to learn more: https://loom.ly/Gm665Qs This breakthrough offers hope for patients and their families, as we continue the battle to end Alzheimer's. Stay informed and spread awareness. Have you come across any other promising advancements in Alzheimer's research? Share your thoughts and experiences in the comments. #AlzheimersResearch #MedicalAdvancements #HopeInTheFight

An exciting announcement from the #FDA has led to the second approved treatment for #Alzheimers. The #regulatoryapproval of #Kisunla (#donanemab), a new #Alzheimerstreatment developed by Eli Lilly and Company, marks a meaningful step forward in addressing #cognitivedecline. This treatment targets and clears #amyloidplaques, slowing early-stage Alzheimer's progression. Unlike other treatments, patients can stop treatment after plaque clearance, reducing costs and potential side effects. While this breakthrough brings hope, as with any new innovative treatment, some questions and uncertainties remain. Nonetheless, this breakthrough represents an important advance in the fight against Alzheimer's and is a source of hope for patients in the early stages of this devastating disease.

Experimental drug slows progression of early Alzheimer's disease by 60%, study finds. So say the headlines on one of Europe's news sites. It's been mentioned that Eli Lilly's experimental drug #donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting recently. But is all that it seems? Well, there are many different interpretations of this data. See attached letter from the lastest BMJ which suggests much less exciting outcomes and highlights some of the serious side effects. There are people on here with much more expertise on these matters than I but I find it interesting the way this 'silver bullet' is being discussed in the media currently. #alzheimers #useyournoggin #lifestyle #bmj #clinicalstudies #newdrugs